Drug Trial Radar · NCT00402363
Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation
Last checked: Nov 20, 2026Latest source record: Jan 30, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
663
Actual
Start
Nov 2006
Primary completion
Jan 2010
Study completion Jan 2010
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 22, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate efficacy and safety of Omacor (omega-3-acid ethyl esters) in patients with recurrent, symptomatic atrial fibrillation.
Conditions
- Fibrillation, Atrial
Interventions
omega-3-acid ethyl estersDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Paroxysmal AF With an Event of Documented Symptomatic Atrial Fibrillation (AF)/FlutterTime frame: From first dose of study drug (Day 1) to the first symptomatic recurrence of AF/flutter (up to Week 24)
Locations
178 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Huntsville, Alabama
GSK Investigational Site
Anchorage, Alaska
GSK Investigational Site
Cottonwood, Arizona
GSK Investigational Site
Mesa, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Fort Smith, Arkansas
GSK Investigational Site
Hot Springs, Arkansas
GSK Investigational Site
Alamada, California
GSK Investigational Site
Bakersfield, California
GSK Investigational Site
Bakersfield, California
GSK Investigational Site
Beverly Hills, California
GSK Investigational Site
Carmichael, California
GSK Investigational Site
Fair Oaks, California
GSK Investigational Site
Fountain Valley, California
GSK Investigational Site
Loma Linda, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Merced, California
GSK Investigational Site
Palm Springs, California
GSK Investigational Site
Poway, California
GSK Investigational Site
Redondo Beach, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
Vista, California
GSK Investigational Site
Walnut Creek, California
GSK Investigational Site
Aurora, Colorado
GSK Investigational Site
Colorado Springs, Colorado
GSK Investigational Site
Littleton, Colorado
GSK Investigational Site
Bridgeport, Connecticut
GSK Investigational Site
Farmington, Connecticut
GSK Investigational Site
Guilford, Connecticut
GSK Investigational Site
Washington D.C., District of Columbia
Showing 40 of 178 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.